You are here: Industry Insights > Janssen

News List

Janssen alums' Aro Biotherapeutics takes aim at centyrins with $13M round fiercebiotech
December 27, 2018
A pair of former Janssen R&D leaders founded Aro Biotherapeutics early this year to develop centyrins—small proteins that could potentially work like antibodies without the accompanying challenges.....
Janssen Submits Application to FDA for Stelara as Ulcerative Colitis Treatment americanpharmaceuticalreview
December 24, 2018
Janssen Pharmaceutical announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of.....
Janssen, OHCA Enter LAIs Contract contractpharma
December 17, 2018
Janssen Pharmaceuticals, Inc. has entered a results-based contract for long-acting injectable schizophrenia medicines (LAIs) with the Oklahoma Health Care Authority (OHCA), which manages Oklahoma's Medicaid plan, SoonerCare.
Janssen Submits sNDA for Xarelto to Prevent VTE in Acute Medically Ill Patients americanpharmaceuticalreview
December 17, 2018
Janssen Pharmaceutical announced the submission of a supplemental New Drug Application (sNDA) for Xarelto (rivaroxaban) to the U.S. Food and Drug Administration (FDA) for the prevention of......
Janssen’s Tremfya shows superiority in plaque psoriasis to Novartis’ drug at 48 weeks pharmaceutical-technology
December 14, 2018
Johnson & Johnson subsidiary Janssen has announced results from its phase III Eclipse trial comparing its Tremfya (guselkumab) with Novartis’ Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis.....
Vect-Horus and Janssen partner for neurodegenerative disease treatment SHARE pharmaceutical-technology
December 13, 2018
Vect-Horus has entered a research collaboration agreement with Johnson & Johnson subsidiary Janssen Pharmaceuticals for treating neurodegenerative diseases.....
Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018 pharmafile
December 07, 2018
Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 data for its combination of Darzalex (daratumumab) alongside lenalidomide
Janssen unveils new data backing wider use of Darzalex pharmatimes
December 06, 2018
Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.
Janssen affiliate Cilag and Argenx sign deal for cancer therapy pharmaceutical-technology
December 05, 2018
Janssen Pharmaceutical affiliate Cilag International has signed a global collaboration and license agreement with Dutch biotechnology company Argenx for cusatuzumab (ARGX-110)....
Janssen's Stelara shows promise across two dosages in ulcerative colitis pharmafile
November 20, 2018
Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two dosage groups

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page